Market closed
MoonLake Immunotherapeutics/$MLTX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
Ticker
$MLTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Zug, Switzerland
Employees
50
Website
MLTX Metrics
BasicAdvanced
$2.8B
-
-$1.30
1.30
-
Price and volume
Market cap
$2.8B
Beta
1.3
52-week high
$58.26
52-week low
$41.27
Average daily volume
404K
Financial strength
Current ratio
25.512
Quick ratio
24.716
Long term debt to equity
0.391
Total debt to equity
0.682
Management effectiveness
Return on assets (TTM)
-13.32%
Return on equity (TTM)
-16.80%
Valuation
Price to book
5.8
Price to tangible book (TTM)
5.8
Price to free cash flow (TTM)
-34.385
Growth
Earnings per share change (TTM)
25.55%
MLTX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for MoonLake Immunotherapeutics stock?
MoonLake Immunotherapeutics (MLTX) has a market cap of $2.8B as of January 29, 2025.
What is the P/E ratio for MoonLake Immunotherapeutics stock?
The price to earnings (P/E) ratio for MoonLake Immunotherapeutics (MLTX) stock is 0 as of January 29, 2025.
Does MoonLake Immunotherapeutics stock pay dividends?
No, MoonLake Immunotherapeutics (MLTX) stock does not pay dividends to its shareholders as of January 29, 2025.
When is the next MoonLake Immunotherapeutics dividend payment date?
MoonLake Immunotherapeutics (MLTX) stock does not pay dividends to its shareholders.
What is the beta indicator for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics (MLTX) has a beta rating of 1.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.